Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP9 | P14780 | 2/20 | 0.32 |
| ▸ | MMP13 | P45452 | 2/20 | 0.32 |
| ▸ | MMP1 | P03956 | 1/20 | 0.32 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.32 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.31 |
| ▸ | MMP8 | P22894 | 2/20 | 0.30 |
| ▸ | MMP14 | P50281 | 2/20 | 0.30 |
| ▸ | MMP2 | P08253 | 1/20 | 0.30 |
| ▸ | MMP3 | P08254 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23325912 | 0.90 | USP30 (0.30) | — | |
| SCHEMBL25905688 | 0.86 | CYP2D6 (0.33) | MMP9MMP13MMP1CYP2D6HRH3 | |
| SCHEMBL23324541 | 0.82 | — | — | |
| SCHEMBL23324939 | 0.80 | OPRM1 (0.33) | MMP9MMP13MMP1 | |
| SCHEMBL25905690 | 0.80 | HRH3 (0.36) | CYP2D6HRH3 | |
| SCHEMBL23324592 | 0.78 | HRH3 (0.30) | HRH3 | |
| SCHEMBL23323492 | 0.76 | USP30 (0.31) | — | |
| SCHEMBL23342602 | 0.74 | DPP4 (0.35) | — | |
| SCHEMBL25884599 | 0.73 | CYP2D6 (0.30) | CYP2D6 | |
| SCHEMBL23323567 | 0.72 | CYP2D6 (0.39) | CYP2D6HRH3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230233569-A1 | METHODS FOR DELAYING, PREVENTING, AND TREATING ACQUIRED RESISTANCE TO RAS INHIBITORS | WILMINGTON TRUST, NATIONAL ASSOCIATION, AS AGENT | 2023-07-27 | — | — | US | disclosed |
| US-20230233569-A1 | METHODS FOR DELAYING, PREVENTING, AND TREATING ACQUIRED RESISTANCE TO RAS INHIBITORS | WILMINGTON TRUST, NATIONAL ASSOCIATION, AS AGENT | 2023-07-27 | — | — | US | disclosed |
| US-20230234929-A1 | RAS INHIBITORS | WILMINGTON TRUST, NATIONAL ASSOCIATION, AS AGENT | 2023-07-27 | — | — | US | disclosed |
| US-20230234929-A1 | RAS INHIBITORS | WILMINGTON TRUST, NATIONAL ASSOCIATION, AS AGENT | 2023-07-27 | — | — | US | disclosed |
| US-11566007-B2 | Ras inhibitors | Revolution Medicines, Inc. (US) | 2023-01-31 | — | — | US | disclosed |
| US-20210130303-A1 | RAS INHIBITORS | WILMINGTON TRUST, NATIONAL ASSOCIATION, AS AGENT | 2021-05-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11566007-B2 | Ras inhibitors | KRAS, NRAS, HRAS | MMP9 3319/4885MMP13 4052/4885MMP1 4721/4885 |
| US-20230234929-A1 | RAS INHIBITORS | KRAS, NRAS, HRAS | MMP9 3319/4885MMP13 4052/4885MMP1 4721/4885 |
| US-20230233569-A1 | METHODS FOR DELAYING, PREVENTING, AND TREATING ACQUIRED RESISTANCE TO RAS INHIBITORS | KRAS, HRAS, MTOR | MMP9 2622/4885MMP13 3988/4885MMP1 4279/4885 |
| US-20210130303-A1 | RAS INHIBITORS | KRAS, NRAS, HRAS | MMP9 3319/4885MMP13 4052/4885MMP1 4721/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.